Related Experiment Videos
Increased plasma cyclic nucleotide concentrations in congestive heart failure
British Heart Journal
|November 1, 1984
Summary
Plasma cyclic adenosine monophosphate (AMP) and guanosine monophosphate (GMP) levels correlate with heart failure severity and pulmonary pressures. Treatment rapidly reduced cyclic AMP and GMP, with higher GMP in mitral stenosis patients.
Area of Science:
- Cardiology
- Biochemistry
- Physiology
Background:
- Heart failure is a complex condition impacting cardiac and systemic physiology.
- Cyclic nucleotides, adenosine monophosphate (AMP) and guanosine monophosphate (GMP), are key intracellular messengers.
- Understanding their role in heart failure pathophysiology is crucial for diagnosis and treatment.
Purpose of the Study:
- To investigate plasma concentrations of cyclic AMP and GMP in patients with heart failure.
- To correlate these levels with heart failure severity, plasma noradrenaline, and pulmonary artery pressures.
- To observe changes in cyclic nucleotide levels during treatment for acute left ventricular failure.
Main Methods:
- Ultrasensitive radioimmunoassay was used to measure plasma cyclic AMP and GMP in 138 heart failure patients.
- Measurements were correlated with New York Heart Association functional classification, plasma noradrenaline, and mean pulmonary artery pressures.
- Serial daily measurements were performed in four patients undergoing treatment for acute left ventricular failure.
Main Results:
- Plasma cyclic AMP concentrations were significantly related to heart failure severity, plasma noradrenaline levels, and pulmonary artery pressures.
- Cyclic AMP levels decreased rapidly following treatment for acute left ventricular failure.
- Plasma cyclic GMP concentrations also correlated with heart failure severity and pulmonary artery pressures, decreasing sharply with treatment but remaining elevated.
- Patients with mitral stenosis exhibited significantly higher cyclic GMP concentrations compared to other heart failure etiologies.
Conclusions:
- Plasma cyclic AMP and GMP levels serve as potential biomarkers for heart failure severity and response to treatment.
- The distinct behavior of cyclic GMP in mitral stenosis warrants further investigation.
- These findings contribute to understanding the role of cyclic nucleotides in the hemodynamic and neurohormonal alterations of heart failure.